Ancora Advisors’s Intellia Therapeutics NTLA Stock Holding History

Ancora Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15	Closed	-$559	–	1870
2023 Q1	$559	Buy	+15	New	+$588	﹤0.01%	1714

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ancora Advisors's NTLA Position: Q2 2023 in Review

Ancora Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 15 shares — an estimated $559 sold.

Ancora Advisors first reported a position in NTLA in Q1 2023 and held it in 1 quarter. The position peaked at $559 in Q1 2023. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

Ancora Advisors reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
Ancora Advisors sold 15 Intellia Therapeutics shares in Q2 2023, an estimated $559.
Ancora Advisors first reported a position in Intellia Therapeutics in Q1 2023 and held it in 1 quarter.
Ancora Advisors's Intellia Therapeutics position peaked at $559 in Q1 2023.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Ancora Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.